In severe, uncontrolled asthma, tezepelumab reduced exacerbations over 1 y regardless of type 2 inflammation level

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)JC128
JournalAnnals of internal medicine
Volume176
Issue number11
DOIs
StatePublished - Nov 1 2023

ASJC Scopus subject areas

  • Internal Medicine

Cite this